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Abstract 
A simple and rapid method involving thermal-desorption gas chromatography with flame ionisation 
detection (TD-GC) has been successfully developed for the determination of ethylene glycol in whole 
blood.  No sample extraction or derivatization steps were required.  The conditions required for the 
direct determination of ethylene glycol in whole blood were optimised and require only the addition 
of the internal standard, 1,2-butanediol to the sample.  A 1 µL aliquot of the sample was then 
introduced to the thermal desorption unit, dried, and thermal desorbed directly to the gas 
chromatograph.  A calibration curve was constructed over the concentration range of 1.0 to 200 mM 
and was found to be linear over the range investigated with an R2 value of 0.9997.  The theoretical 
limit of detection, based on 3 σ was calculated to be 50.2 µM (3.11 mg/L).  No issues with carryover 
were recorded.  No interferences were recorded from endogenous blood components or a number 
of commonly occurring alcohols.  The proposed method was evaluated by carrying out replicate 
ethylene glycol determinations on fortified whole blood samples at levels of 12.5 mM, 20.0 mM, 
31.2 mM, 100 mM and 200 mM comparable with commonly reported blood levels in intoxications.  
Mean recoveries of between 84.8 % and 107 % were obtained with coefficients of variation of 
between 1.7 % and 5.8 %.  This data suggests that the method holds promise for applications in 
toxicology and where a rapid, reliable method to confirm ethylene glycol poisoning is required. 
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Introduction 
Ethylene glycol is a common organic solvent that has a wide range of uses, such as antifreeze in 
vehicles, brake fluid, and as a chemical feedstock for polymer manufacture. Ethylene glycol is an 
odourless, colourless chemical with a sweet taste that produces effects similar to that of ethanol 1 
with a dose of 1.4–1.6 mg/kg 2 considered a lethal dose in adults. Due to the sweet tasting nature of 
ethylene glycol and its ease of availability it is a commonly seen poison within emergency medicine 
in both humans and animals. Cases of ethylene glycol poisonings are rare within the United 
Kingdom, in the NPIS report of the year 2015/16 a total of 68 cases of poisoning were recorded. 3  
However, cases are more prevalent within the United States of America; in their annual report of 
2015, the American Association of Poison Control Centers reported a total of 6204 cases of ethylene 
glycol exposure resulting in 22 deaths and 178 major injuries. 4 
Ethylene glycol is itself is sparingly toxic; once ingested into the body the minority (20 %) of ethylene 
glycol is excreted unchanged 5 and initial consumption results in symptoms of intoxication similar to 
that seen with ethanol.  The remanding ethylene glycol is converted by the action of alcohol 
dehydrogenase into glycoaldehyde, which is then further metabolised to glycolic acid, glyoxylic acid 
and finally oxalic acid 5 resulting in acidosis and its associated adverse effects.  Oxalic acid can then 
combine with calcium to form calcium oxalate crystals. These crystals precipitate in many organs, 
but are particularly toxic to the kidneys, resulting in renal failure. The average elimination half-life of 
ethylene glycol is about 3 hours, with metabolites having a biological half-life in the order of many 
days. 6   
The current accepted method for the treatment of ethylene glycol poisonings is the administration 
of either ethanol or fomepizole (4-methylpyrazole) once a patient is stabilized and acidosis 
corrected.  These treatments work via interfering with the oxidation of ethylene glycol by alcohol 
dehydrogenase and preventing its metabolism. These treatments are usually continued until serum 
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ethylene glycol concentrations fall below 20 mg/dL and, coupled with haemodialysis, generally 
provide a positive outcome in cases where diagnosis is made early enough. 7 
Detection of ethylene glycol is very analytical challenging and possible poisoning is often diagnosed 
by analysis of serum osmol and anion gap. 5,8,9  However, these changes are not always easily 
detectable and as a result alternative methods for the determination of ethylene glycol poisoning 
have been sought. 8  Methods based on the detection of other common components of ethylene 
glycol antifreeze formulations, such as fluorescein, have been reported. 10  These offer a simple 
method for the detection of ethylene glycol consumption by measuring the fluorescence resulting 
from the dye in urine, but as a result can be non-specific.  Enzyme-based assays have also been 
developed, but generally can only detect high concentrations (300 mg/dL). 11   The small molecular 
mass of ethylene glycol does not lend itself to LC/MS and other HPLC approaches suffer from the 
lack of a chromophore, requiring Refractive Index detection, 12 which lacks specificity and sensitivity.    
Presently, gas chromatography (GC) is the most commonly employed laboratory based approach.  
However, methods are laborious and potentially problematic; based on headspace, direct aqueous 
injection, or requiring complex derivatisation steps (Table 1).  Methods based on the derivatisation 
of ethylene glycol 13 can be lengthy 14 and complicated, requiring reagents to remove water for the 
derivatisation reaction to occur.  Isolation by liquid or solid-phase extraction is hampered by the 
polar nature of ethylene glycol.  To overcome these problems, direct injections of aqueous dilutions 
of serum or urine have been attempted. 15  However, water is a relatively poor solvent for gas 
chromatography and injections can result in poor peak shape and non-reproducible retention times.  
The co-introduction of serum or urine components can also severely limit the analytical life span of 
the column and lead to problems with carryover and sensitivity.  Headspace analysis similarly 
suffers, as the high water content present in biological fluids can result in co-injection of water and 
its introduction to the GC.   
4 
 
However, studies have shown the possibility of determining other alcohols such as ethanol in blood 
by pyrolysis-gas chromatography. 16  We believe a similar approach such as thermal desorption-gas 
chromatography (TDC-GC) could be used to determine ethylene glycol.  This would allow for the 
rapid, automated extraction, drying and introduction of sample overcoming the issues suffered by 
other GC methods.  In this present investigation, we first explore this possibility and then optimise 
the conditions required for the TDC-GC determination of ethylene glycol in µL volumes of whole 
blood directly without the need for extraction or derivatization.   
We believe it possible to thermally desorb ethylene glycol present in samples of both water and 
whole blood using a commercial pyrolysis thermal desorption unit connected to a gas 
chromatograph (TD-GC) with flame ionisation detection (FID) for quantification.  Samples of whole 
blood or aqueous analytical standards are first dried at low temperature and then thermally 
desorbed and focused onto a Tenax® cartridge.  The dried focused compounds can then be thermally 
transferred to the inlet of the GC and then separated and detected by FID.  After analysis the 
remaining blood residues are effectively removed by pyrolysis at high temperature.  In the following 
sections we have optimised the conditions required for this procedure and shown the possibility of 
determining forensically and toxicologically relevant concentrations of ethylene glycol in whole 
blood. 
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Technique  Sample Detection 
limit, mg/L  
Comment Ref. 
GC- DMS Human saliva 100  Saliva volatiles collected on a polydimethylsiloxane coated titanium cylinder and thermally desorbed 
to the GC. 
17 
GC/MS Human plasma 5.0  De-proteinated with acetic acid; vortex; centrifugation; supernatant spiked with internal standard; 
reaction with butylboronic acid; neutralize with NH4OH, extraction with dichloromethane; 
concentration. 
18 
GC/MS Human serum 10 Acetic acid/acetonitrile containing the internal standard, 1,3-propanediol add to the serum sample to 
precipitate proteins. Following centrifugation, 2,2-dimethoxypropane/dimethylformamide added to 
convert water to methanol, and the volume reduced to < 100 µL of dimethylformamide. Introduced to 
GC/MS after formation of tert-butyldimethylsilyl derivative. 
19
 
GC/MS Human plasma 50 (limit of 
quantitation). 
Samples (50 µL) vortex mixed with internal standard and centrifuged.  Supernatant extracted with 
DMF and derivatization with BSTFA. 
20 
GC/MS Human blood 0.001 
(estimated) 
Whole blood was fortified with isotopically labelled ethylene glycol and extracted/deproteinated with 
acetonitrile and derivatised with heptafluorobutyric anhydride. The resulting derivatives extracted 
with n-hexane. 
21 
GC/MS Human serum 
and urine 
50 Samples of urine or serum mixed with borate buffer and the internal standards: 1,3-propylene glycol, 
IS2: (3-(4-chlorophenyl) propionic acid added. Isobutanol and pyridine added and the mixture and 
derivatization phenylboronic acid undertaken.  
22 
GC/FID Human serum 
and urine 
31 (limit of 
quantification
) 
Direct Injection of serum or urine samples diluted with water containing 2,3-butanediol as Internal 
standard. 
23 
GC/FID Human serum 
and urine 
25 Samples of urine or serum mixed with borate buffer and the internal standards: 1,3-propylene glycol, 
IS2: (3-(4-chlorophenyl) propionic acid added. Isobutanol and pyridine added and the mixture and 
derivatization phenylboronic acid undertaken. 
24 
GC/FID Human serum  Internal standard (in acetonitrile) added to sample; centrifugation to remove protein precipitate; 
esterification with butylboronic acid and 2,2-dimethoxypropane; neutralization with NH4OH in 
acetonitrile. 
25 
GC/FID Human serum 25  Serum samples were deproteinated using ultrafiltration and 1 µL was injected directly to GC. 
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GC/FID Human plasma 
and serum 
10 Headspace GC using 1,3-propanediol as an internal standard following derivatization with 
phenylboronic acid. 
26 
GC/FID Human plasma 20.8 (lower 
limit of 
quantification
) 
Sample extracted with 2:1 (v:v) acetonitrile containing internal standard 1,2 butanediol. 
27 
HPLC/UV Human serum 3.1  Extraction from salted, acidified serum using methyl ethyl ketone followed by removal of organic 
28 
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phase and evaporation to dryness and derivatization with PNBDI. 
TLC Urine  Acidification; extraction with CHCl3; concentration; TLC. 
29 
HPLC/UV Human plasma 0.15  Heparinized blood deproteinated by addition of acetonitrile and phosphate buffer (pH 7), 
centrifugation, removal of solvent and evaporation to dryness. 
30 
HPLC/UV and 
LC/MS 
Water 1.0 (UV), 0.03 
(MS) 
Following derivatization with benzoyl chloride benzoyl esters of glycols are separated by microcolumn 
reversed-phase HPLC with either UV (237 nm) or electrospray ionization mass spectrometric (ESI-MS) 
detection using selected ion monitoring. 
31 
LC/MS Human Serum 1.1 Derivatization of ethylene glycol with benzoyl chloride in serum sample. Mixtures then extracted with 
pentane and blown down to dryness. Extract re-constituted in mobile phase.   
32 
GC/FTIR Water 120  Direct Injection. 
33 
GC-MS Human Serum 5.0  Derivatization with perfluorooctyl. 
34 
GC/ECD Human serum 0.38  Acetonitrile with internal standard added to sample; centrifugation; concentration; extraction with p-
bromophenyl boric acid in ethyl acetate. 
35 
UV-Vis 
spectroscopy 
Human serum 62.1  Colorimetric: precipitation of protein with trichloroacetic acid followed by centrifugation, addition of 
chromotropic acid, heating, and dilution. Absorbance at 580 nm. 
36 
GC/FID Air  Sample adsorbed on Amberlite® XAD-2 with personal sampling pump; extraction with diethyl ether. 
37 
GC/FID Hydrocarbon 
based or synthetic 
lubricants 
1.0 Derivatization of ethylene glycol with phenyl boronic acid in lubricant sample followed by headspace 
GC analysis.   
38 
GC/FID Beer 0.73  Addition of ammonium sulfate and then extracted with ethyl acetate. 
39 
GC/FID Whole blood 3.11  Direct thermal desorption gas chromatography of 1 µL of whole blood. This 
method 
Gas chromatography/differential mobility spectrometry (GC/DMS); Gas chromatography/mass spectroscopy (GC/MS); Gas chromatography flame ionisation detection 
(GC/FID); High performance liquid chromatography UV detection (HPLC/UV); Gas chromatography/Fourier transformer infrared detection (GC/FTIR); Gas 
chromatography/electron capture detection (GC/ECD); Thin layer chromatography (TLC). 
Table 1.  Previously reported methods for the determination of ethylene glycol 
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Experimental  
Chemical and Reagents  
All reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless otherwise stated.  Deionised 
water was obtained from a Purite RO200–Stillplus HP System, (Purite Oxon, UK).  Defibrinated horse 
blood was obtained from Fisher Scientific (Loughborough, UK).  Blood collection was carried out by 
the supplier in stress-free conditions by qualified, trained personnel in accordance with the Animals 
(Scientific Procedures) Act 1986. 
Instrumentation 
The CDS 5200 pyrolysis thermal desorption instrument conditions were as follows: Drying 
temperature 100 °C for 20 s; desorption temperature 250 °C for 2 min.  Transfer line 250 °C, cleaning 
temperature, 1100 °C for 10 s.  Gas chromatography analysis was carried out using an Agilent 6890 
instrument with flame ionisation detection.  Sample extracts were introduced via a CDS 5200 
pyrolysis thermal desorption instrument (CDS Analytical, Oxford, PA) on to a HP-5 capillary column 
(15 m x 0.25 mm ID, 0.25 µm film thickness, 5 % diphenyl–95 % dimethylsiloxane phase).  The GC 
oven temperature was maintained at 100 °C for 2 min and then programmed to 250 °C at 20 °C/min 
and finally held isothermally for 10.5 min at this temperature. The injector and flame ionisation 
detector were held at 250 °C and 260 °C respectively.   
Sample Analysis 
A scheme for the analysis of blood samples is given in figure 1.  Whole blood samples were diluted in 
ratio of one-to-one with deionised water containing 50 mM of internal standard, 1,2-butanediol.  A 
suitable aliquot of this solution (0.5 – 1.0 µL) or aqueous analytical standard was then pipetted into a 
quartz pyrolysis tube containing a plug of salinized glass wool and placed into the pyrolysis probe.  
The remainder of the procedure was then carried out under the automated control of the CDS 5200 
pyrolysis thermal desorption instrument.  The tube was heated in the pyrolysis probe at 100 °C for 
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20 s to dry the sample.  The probe was then inserted into the thermal desorption instrument and 
heated to 250 °C in an inert atmosphere (He) to thermally desorb the sample components from this 
residue.  The resulting vapour was then focused onto an integrated Tenax® cartridge and thermally 
desorbed to the gas chromatograph and oven temperature program initiated.  The pyrolysis probe 
was then removed and remaining extracted sample residue contained in the quartz pyrolysis tube 
removed by heating at 1100 °C for 10 s.  Periodic cleaning of the quartz pyrolysis tube crucible was 
undertaken with acetone with the aid of ultrasonication. 
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Figure 1.  Flow diagram of ethylene glycol determination in whole blood sample by TD-GC. 
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Results and Discussion 
Proposed Analytical Procedure 
Optimisation of Thermal Desorption Conditions  
The effect of drying time on aqueous solution of 25 mM ethylene glycol was first investigated.  
Figure 2 shows the resulting peak height of the ethylene glycol standard.  As can be seen the 
maximum response was obtained using a drying time of 20 s.  Consequently, further studies were 
made using these conditions.  We next investigated the effect of desorption temperature of 
ethylene glycol from the quartz pyrolysis tube over the range 150 °C to 325 °C.  Figure 3 shows the 
relative peak height responses for an aqueous 25 mM ethylene glycol standard.  A temperature of 
250 °C was found to be optimum, in terms of both sensitivity and precision and was used in further 
studies.  Studies were then made on the effect of time on the desorption of ethylene glycol from the 
Tenax® to the GC.  Figure 4 shows that the optimum time based on both precision and response was 
2 minutes.  This time was hence used in further investigations. 
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Figure 2.  Effect of drying time on ethylene glycol chromatographic peak height. 
12 
 
 
Figure 3.  Effect of desorption temperature on ethylene glycol chromatographic peak height. 
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Figure 4.  Effect of desorption time based on resulting ethylene glycol chromatographic peak height. 
  
14 
 
Precision, Calibration Plot, Limit of Detection and Quantification 
Standard solutions containing ethylene glycol in the concentration range 0.05 - 500 mM were 
prepared in deionised water and determined by the optimized TD-GC procedure.  This range was 
chosen as it covers the lower limit for antidote treatment through to severe toxic levels. 40  The 
calibration plot was found to be linear over the range 1.0 to 200 mM with an R2 value of 0.9997.  The 
theoretical limit of detection, based on 3 σ, was calculated as 50.2 µM (3.11 mg/L) of ethylene glycol 
for a 1 µL sample and the limit of quantification was defined to be 1.0 mM (62.1 mg/L).  It should be 
noted that larger sample volumes can be utilised and hence greater sensitivity can be obtained.   
Studies of Possible Interferences  
Ethanol, methanol, lactic acid, fomepizole (4-methylpyrazole) and glycolic acid, as well as γ-
butyrolactone and 1,4-butanediol were investigated at concentrations of 45 mM as possible 
interferences for the determination of ethylene glycol at a concentration of 45 mM.  At this 
concentration; ethanol, methanol, lactic acid and glycolic acid were not detected and did not 
interfere with the determination of ethylene glycol.  Fomepizole, γ-butyrolactone and 1,4-butanediol 
were found to co-elute with each other, but were all fully resolved from the chromatographic peaks 
for both ethylene glycol and the internal standard, 1,2-butanediol and hence did not interfere with 
the determination of ethylene glycol.  Figure 5 shows a typical chromatogram for a solution 
containing: ethanol, methanol, fomepizole, lactic acid, γ-butyrolactone, 1,4-butanediol ethylene 
glycol all at concentrations of 45 mM along with the internal standard 1,2-butanediol.  As can be 
clearly seen, both ethylene glycol and the internal standard are well-resolved and the quantification 
of ethylene is unaffected.  Investigations of possible carryover for a 200 mM ethylene glycol 
standard showed less than 2 % for a subsequently injected blank. 
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Compound RT, min RRT, min 
methanol ND ND 
ethanol ND ND 
1,4-butandiol  4.19 1.16 
1,2-butandiol 3.60 1.00 
γ-butyrolactone 4.06 1.13 
fomepizole  4.17 1.16 
lactic acid  4.86 1.35 
ethylene glycol 3.20 0.89 
 
Table 2.  Retention times (RT) and relative retention times (RRT) (Analyte RT/Internal standard RT) 
for possible interfering compounds.  ND = not detected. 
 
 
Figure 5. Gas chromatogram showing the separation of ethylene glycol (i) and the internal standard, 
1,2-butanediol (ii) in presence of methanol (ND), ethanol (ND), 1,4-butanediol (iii), ɣ- butyrolactone 
(iv) and fomepizole (v); 45 mM of each compound.  No further peaks were detected after 6 minutes.  
ND = not detected. 
Analytical Application 
To assess the performance of the optimised TD-GC method, replicate determinations of ethylene 
glycol in fortified and unfortified whole blood samples were undertaken.  Blood samples were 
fortified to be 12.5 mM, 20.0 mM, 31.2 mM, 100 mM and 200 mM ethylene glycol.  The appropriate 
volume of internal standard was added to the whole blood and quantification was achieved by 
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external calibration. Figure 6 shows representative chromatograms for samples of whole blood (a) 
fortified with 31.2 mM ethylene glycol and (b) unadulterated whole blood.   
Recoveries and precision data gained for the blood samples fortified with ethylene glycol are 
summarized in Table 3.  These levels were selected as previous investigations have shown blood 
samples taken from human and animal victims to contain levels of ethylene glycol over this range. 
13,22,23,41  The extracts showed well defined signals for ethylene glycol under the conditions described. 
The method can be seen to give reliable data over the concentration ranges investigated.  The use of 
blood sample volumes as small as a µL offers advantages in both health and safety and to areas such 
as forensic and biomedical sciences where large sample volumes may not be obtainable.  Blood 
samples stored at 4° C were found to be stable for at least two weeks. 
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Figure 6.  Representative chromatograms of whole blood samples obtained by TD-GC for (a) whole 
blood (b) whole blood with internal standard (1,2-butanediol) 3.6 minutes (c) whole blood with 
ethylene glycol (3.2 minutes) and internal standard. 
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Blood 
Sample 
Native Added, mM Mean Found, 
mM 
% Mean 
Recovery 
%CV 
1 ND 12.5 10.5 84.8 4.4 
2 ND 20.0 19.5 96.7 2.3 
3 ND 32.2 29.4 94.3 5.8 
4 ND 100 107 107 3.9 
5 ND 200 209 105 1.7 
ND = not detected; %CV = percentage coefficient of variation 
Table 3. Recovery and Precision Data for ethylene glycol obtained on whole blood  
Conclusions 
Our method requires very little sample preparation, requiring only the simple addition of internal 
standard to a whole blood sample.  Other workers (table 1) have reported GC based assays for 
ethylene glycol, but these required rigorous extraction and derivatization procedures.  Therefore, 
the overall time and skill required for these assays is much greater than our proposed assay, which is 
an important consideration in medical and forensic investigations. 7  In addition, a derivatization 
reagent itself and its reaction by-products might be expected to give responses with similar 
retention times to that of ethylene glycol itself. 
Although other workers have also reported on the detection of ethylene glycol in biological fluids, it 
does not appear that they have the required speed and simplicity needed for rapid toxicological 
analysis.  It would be readily simple to also determine ethylene glycol concentrations in dry blood 
samples important in forensic analysis as the TD-GC can be readily applied for solid samples.  As far 
as we are aware, our report is the first to describe the use of a TD-GC assay for the detection of any 
glycol.  However, we believe that the approach developed here could form the basis of a generic 
approach for the analysis of other alcohols, and in future studies, we plan to investigate this further.  
No extraction or derivatization steps were required and the assay was free from interference from 
common endogenous blood components or other structurally similar compounds.  The small 
volumes of blood (µL) utilised offer advantages for health and safety of the analyst and in forensic 
and biomedical investigations where obtaining large samples can be a problem. 
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